Application of estimand framework in ICH E9 (R1) to safety evaluation

References

• Akacha, M., J. Branson, F. Bretz, B. Dharan, P. Gallo, I. Gathmann, R. Hemmings, J. Jones, D. Xi, and E. Zuber. 2020. Challenges in assessing the impact of the covid-19 pandemic on the integrity and interpretability of clinical trials. Statistics in Biopharmaceutical Research 12 (4):419–426. doi:10.1080/19466315.2020.1788984.
   PubMed Web of Science ®Google Scholar
• Akacha, M., F. Bretz, and S. Ruberg. 2016. Estimands in clinical trials – broadening the perspective. Statistics in Medicine 36 (1):5–19. doi:10.1002/sim.7033.
   PubMed Web of Science ®Google Scholar
• Chuang-Stein, C., and M. Beltangady. 2011. Reporting cumulative proportion of subjects with an adverse event based on data from multiple studies. Pharmaceutical Statistics 10 (1):3–7. doi:10.1002/pst.397.
   PubMed Web of Science ®Google Scholar
• Crowe, B., C. Chuang-Stein, S. Lettis, and A. Brueckner. 2016. Reporting adverse drug reactions in product labels. Ther Innov Regul Sci 50 (4):455–463. doi:10.1177/2168479016628574.
   PubMed Web of Science ®Google Scholar
• FDA (Food and Drug Administration). 2005a Development and use of risk minimization action plans. Accessed December 1, 2021. https://www.fda.gov/media/71268/download
   Google Scholar
• FDA (Food and Drug Administration). 2005b. Good pharmacovigilance practices and pharmacoepidemiologic assessment. Plans. Accessed December 1, 2021. https://www.fda.gov/media/71546/download
   Google Scholar
• FDA (Food and Drug Administration). 2005c. Premarketing risk assessment. Accessed December 1, 2021. https://www.fda.gov/media/71650/download
   Google Scholar
• FDA (Food and Drug Administration). 2018. Meta-analyses of randomized controlled clinical trials to evaluate the safety of human drugs or biological products guidance for industry December 1, 2021. https://www.fda.gov/media/117976/download
   Google Scholar
• FDA (Food and Drug Administration). 2021, Sponsor responsibilities—safety reporting requirements and safety assessment for ind and bioavailability/bioequivalence studies, Accessed December 1, 2021. https://www.fda.gov/media/150356/download.
   Google Scholar
• Fine, J. P., and R. J. Gray. 1999. A proportional hazards model for the subdistribution of a competing risk. Journal of the American Statistical Association 94 (446):496–509. doi:10.1080/01621459.1999.10474144.
   Web of Science ®Google Scholar
• Hendrickson, B. A., W. Wang, G. Ball, D. Bennett, A. Bhattacharyya, M. Fries, J. Kuebler, R. Kurek, C. McShea, and L. Tremmel. 2021. Aggregate safety assessment planning for the drug development life-cycle. Ther Innov Regul Sci 55 (4):717–732. doi:10.1007/s43441-021-00271-2.
   PubMed Web of Science ®Google Scholar
• ICH (International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use). 2019a. ICH E9 STATISTICAL PRINCIPLES for CLINICAL TRIALS. Accessed December 1, 2021. https://database.ich.org/sites/default/files/E9_Guideline.pdf
   Google Scholar
• ICH (International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use). 2019b. ICH E9 (R1) ADDENDUM ON ESTIMANDS AND SENSITIVITY ANALYSIS IN CLINICAL TRIALS TO THE GUIDELINE ON STATISTICAL PRINCIPLES FOR CLINICAL TRIALS. Accessed December 1, 2021. https://database.ich.org/sites/default/files/E9-R1_Step4_Guideline_2019_1203.pdf.
   Google Scholar
• Mallinckrodt, C. H., J. Bell, G. Liu, B. Ratitch, M. O’kelly, I. Lipkovich, P. Singh, L. Xu, and G. Molenberghs. 2020. Aligning estimators with estimands in clinical trials: Putting the ICH E9 (R1) guidelines into practice. Therapeutic Innovation & Regulatory Science 54 (2):353–364. doi:10.1007/s43441-019-00063-9.
   PubMed Web of Science ®Google Scholar
• Meyer, R. D., B. Ratitch, M. Wolbers, O. Marchenko, H. Quan, D. Li, C. Fletcher, X. Li, D. Wright, Y. Shentu, et al. 2020. Statistical issues and recommendations for clinical trials conducted during the COVID-19pandemic. Statistics in Biopharmaceutical Research 12 (4):399–411. doi:10.1080/19466315.2020.1779122.
   PubMed Web of Science ®Google Scholar
• Nilsson, M., B. Crowe, G. Anglin, G. Ball, M. Munsaka, S. Shahin, and W. Wang. 2020. Clinical trial drug safety assessment for studies and submissions impacted by COVID-19. Statistics in Biopharmaceutical Research 12 (4):498–505. doi:10.1080/19466315.2020.1804444.
   PubMed Web of Science ®Google Scholar
• Popat, V, M. Soukup, N. Beasley, Y. Pei. 2022. Overview of the Standard Safety Tables and Figures Integrated Guide, It presented at Duke Margolis-FDA Workshop: Advancing Premarket Safety Analytics, Virtual Meeting, December 14.
   Google Scholar
• Rockhold, F. W., A. Lindblad, J. P. Siegel, and G. Molenberghs. 2019. University of Pennsylvania 11th annual conference on statistical issues in clinical trials: Estimands, missing data and sensitivity analysis (morning panel session). Clin Trials 16 (4):350–362. doi:10.1177/1740774519853573.
   PubMed Web of Science ®Google Scholar
• Schmid, P., J. Cortes, L. Pusztai, H. McArthur, S. Kümmel, J. Bergh, C. Denkert, Y. H. Park, R. Hui, N. Harbeck, et al. 2020. Pembrolizumab for early triple-negative breast cancer. The New England Journal of Medicine 382 (9):810–821. doi:10.1056/NEJMoa1910549.
   PubMed Web of Science ®Google Scholar
• Simpson, E. H. 1951. The Interpretation of Interaction in Contingency Tables. Journal of the Royal Statistical Society: Series B (Methodological) 13 (2):238–241. doi:10.1111/j.2517-6161.1951.tb00088.x.
   Web of Science ®Google Scholar
• Unkel, S., M. Amiri, N. Benda, J. Beyersmann, D. Knoerzer, K. Kupas, F. Langer, F. Leverkus, A. Loos, C. Ose, et al. 2019. On estimands and the analysis of adverse events in the presence of varying follow-up times within the benefit assessment of therapies. Pharm Stat 18 (2):166–183. doi:10.1002/pst.1915.
   PubMed Web of Science ®Google Scholar
• Wang, W., Munsaka M., Buchanan J., & Li J., (Eds.). 2021. Quantitative Drug Safety and Benefit Risk Evaluation: Practical and Cross-Disciplinary Approaches(1st ed.). Chapman and Hall/CRC. doi:10.1201/9780429488801.
   Google Scholar
• Yang, F., J. Wittes, and B. Pitt. 2019. Beware of on-treatment safety analyses. Clin Trials 16 (1):63–70. doi:10.1177/1740774518812774.
   PubMed Web of Science ®Google Scholar
• Zhou, Y., C. Ke, Q. Jiang, S. Shahin, and S. Snapinn. 2015. Choosing appropriate metrics to evaluate adverse events in safety evaluation. Ther Innov Regul Sci 49 (3):398–404. doi:10.1177/2168479014565470.
   PubMed Web of Science ®Google Scholar